Bharat Biotech and the University of Sydney Infectious Diseases Institute have signed a Memorandum of Understanding (MoU) to enhance vaccine research, bolster academic-industry relationships, and support worldwide endeavors against infectious diseases. This collaboration seeks to foster strong partnerships within the sector and across organizations to develop innovative approaches in addressing upcoming epidemics and infectious diseases.
Bharat Biotech, based in Hyderabad, stated that they will harness the combined strengths of academia and industry to advance the field of vaccines and biotherapeutics. Dr. Krishna Ella, Executive Chairman of Bharat Biotech, highlighted that this partnership aligns with their commitment to collaborative research, fostering innovation, and furthering advancements in vaccine technology.
Professor Jamie Triccas, Deputy Director of Sydney ID, underscored the importance of this collaboration by stating that positioning Sydney ID on a global platform to drive innovation and showcase expertise in developing new vaccines and biotherapeutics is crucial. He emphasized the significant societal and reputational impacts of creating new vaccines that effectively eradicate diseases in both humans and animals, which are safe, affordable, and efficient. Together with Bharat Biotech International Limited, their aim is to create a lasting positive influence on global health.
